{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T17:28:36Z","timestamp":1784914116947,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","prd-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism & Related Disorders"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.parkreldis.2018.12.002","type":"journal-article","created":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T12:39:36Z","timestamp":1544531976000},"page":"57-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Use of botulinum toxin in Parkinson's disease"],"prefix":"10.1016","volume":"59","author":[{"given":"Angeline","family":"Jocson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Lew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.parkreldis.2018.12.002_bib1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.11138\/FNeur\/2018.33.1.007","article-title":"Pharmacological differences and clinical implications of various botulinum toxin preparations: a critical appraisal","volume":"33","author":"Ferrari","year":"2018","journal-title":"Funct. Neurol."},{"issue":"8","key":"10.1016\/j.parkreldis.2018.12.002_bib2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/mds.27072","article-title":"Botulinum toxin: state of the art","volume":"32","author":"Jankovic","year":"2017","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.12.002_bib3","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1002\/mds.20793","article-title":"Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study","volume":"21","author":"Lagalla","year":"2006","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.002_bib4","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/mds.10420","article-title":"Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism","volume":"18","author":"Mancini","year":"2003","journal-title":"Mov. Disord."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.12.002_bib5","article-title":"RimabotulinumtoxinB in sialorrhea: systematic review of clinical trials","volume":"4","author":"Dashtipour","year":"2017","journal-title":"Journal of Clinical Movement Disorders"},{"issue":"2","key":"10.1016\/j.parkreldis.2018.12.002_bib6","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mds.23929","article-title":"\u201cSafety and efficacy of botulinum toxin type B for treatment of sialorrhea in Parkinson's disease: a prospective double-blind trial","volume":"27","author":"Chinnapongse","year":"2012","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.parkreldis.2016.07.001","article-title":"\u201cDrooling in Parkinson's disease: a randomized controlled trial of incobotulinum toxin A and meta-analysis of Botulinum toxins","volume":"30","author":"Narayanaswami","year":"2016","journal-title":"Park. Relat. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.002_bib8","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1586\/14737175.7.6.637","article-title":"Botulinum toxin in the treatment of tremors, dystonias, sialorrhea and other symptoms associated with Parkinson's disease","volume":"7","author":"Sheffield","year":"2007","journal-title":"Expert Rev. Neurother."},{"issue":"3","key":"10.1016\/j.parkreldis.2018.12.002_bib9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mds.870100317","article-title":"\u2019Off\u2019 painful dystonia in Parkinson's disease treated with botulinum toxin","volume":"10","author":"Pacchetti","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib10","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.parkreldis.2017.10.009","article-title":"Incobotulinum toxin A in Parkinson's disease with foot dystonia: a double blind randomized trial","volume":"46","author":"Rieu","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib11","article-title":"The use of botulinum toxin to treat \u2018striatal toes\u2019","volume":"659","author":"Giladi","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.12.002_bib12","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/mds.1186","article-title":"Treatment of dystonic clenched fist with botulinum toxin","volume":"16","author":"Cordivari","year":"2001","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib13","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2340\/16501977-2094","article-title":"Botulinum toxin for Foot Dystonia in patients with Parkinson's disease having deep brain stimulation: a case series and a pilot study","volume":"48","author":"Gupta","year":"2016","journal-title":"J. Rehabil. Med."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib14","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1017\/cjn.2016.279","article-title":"Botulinum toxin use in refractory pain and other symptoms in parkinsonism","volume":"43","author":"Bruno","year":"2016","journal-title":"Can. J. Neurol. Sci."},{"issue":"9","key":"10.1016\/j.parkreldis.2018.12.002_bib15","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1016\/j.mayocp.2017.06.010","article-title":"Botulinum toxin in Parkinson disease tremor: a randomized, double-blind, placebo-controlled study with a customized injection approach","volume":"92","author":"Mittal","year":"2017","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5334\/tohm.240","article-title":"Effective management of upper limb parkinsonian tremor by IncobotulinumtoxinA injections using sensor-based biomechanical patterns","volume":"5","author":"Rahimi","year":"2015","journal-title":"Tremor and Other Hyperkinetic Movements"},{"issue":"10","key":"10.1016\/j.parkreldis.2018.12.002_bib17","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/mds.21019","article-title":"Botulinum toxin a may Be efficacious as treatment for jaw tremor in Parkinson's disease","volume":"21","author":"Schneider","year":"2006","journal-title":"Mov. Disord."},{"issue":"5","key":"10.1016\/j.parkreldis.2018.12.002_bib18","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/mds.23522","article-title":"Botulinum toxin type A for levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio","volume":"26","author":"Espay","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib19","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1007\/s004150170134","article-title":"The effect of botulinum toxin injections to the calf muscles on freezing of gait in parkinsonism: a pilot study","volume":"248","author":"Giladi","year":"2001","journal-title":"J. Neurol."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.002_bib20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/mds.21396","article-title":"The effect of injecting botulinum toxin type A into the calf muscles on freezing of gait in Parkinson's disease: a double blind placebo-controlled pilot study","volume":"22","author":"Gurevich","year":"2007","journal-title":"Mov. Disord."},{"issue":"7","key":"10.1016\/j.parkreldis.2018.12.002_bib21","first-page":"CR282","article-title":"Botulinum toxin type B for gait freezing in Parkinson's disease","volume":"10","author":"Fernandez","year":"2014","journal-title":"Med Sci Monit"},{"issue":"2","key":"10.1016\/j.parkreldis.2018.12.002_bib22","first-page":"147","article-title":"\u201cBotulinum toxin treatment of freezing of gait in Parkinson's disease patients as reflected in functional magnetic resonance imaging of leg movement","volume":"37","author":"Vastik","year":"2016","journal-title":"Neuroendocrinol. Lett."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib23","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1212\/01.wnl.0000171857.09079.9f","article-title":"Camptocormia: pathogenesis, classification, and response to therapy","volume":"65","author":"Azher","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2018.12.002_bib24","first-page":"1","article-title":"\u201cOutcomes of intradetrusor onabotulinum toxin A injection in patients with Parkinson's Disease","author":"Vurture","year":"2018","journal-title":"Neurourol. Urodyn."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.12.002_bib25","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.urology.2013.09.017","article-title":"OnabotulinumtoxinA office treatment for neurogenic bladder incontinence in Parkinson's disease","volume":"83","author":"Anderson","year":"2014","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.002_bib26","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1111\/j.1572-0241.2003.07514.x","article-title":"\u201cTreatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A","volume":"98","author":"Albanese","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib27","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1111\/j.1365-2036.2005.02669.x","article-title":"Outlet type constipation in Parkinson's disease: results of botulinum toxin treatment","volume":"22","author":"Cadeddu","year":"2005","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"15","key":"10.1016\/j.parkreldis.2018.12.002_bib28","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1056\/NEJM200204113461517","article-title":"Botulinum toxin for cricopharyngeal dysfunction in Parkinson's disease","volume":"346","author":"Restivo","year":"2002","journal-title":"NEJM"},{"key":"10.1016\/j.parkreldis.2018.12.002_bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1136\/jnnp.2009.174698","article-title":"An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment","volume":"81","author":"Alfonsi","year":"2010","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"1","key":"10.1016\/j.parkreldis.2018.12.002_bib30","doi-asserted-by":"crossref","DOI":"10.1111\/j.1749-6632.2002.tb02861.x","article-title":"Botulinum toxin therapy for apraxia of lid opening","volume":"956","author":"Boghen","year":"2006","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"4","key":"10.1016\/j.parkreldis.2018.12.002_bib31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1002\/mds.870100425","article-title":"Communication: botulinum A Toxin for the so-called apraxia of lid opening","volume":"10","author":"Lepore","year":"1995","journal-title":"Mov. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib32","doi-asserted-by":"crossref","first-page":"286","DOI":"10.5334\/tohm.186","article-title":"Comparable botulinum toxin outcomes between primary and secondary blepharospasm: a retrospective analysis","volume":"4","author":"Martinez-Ramirez","year":"2014","journal-title":"Tremor Other Hyperkinet Mov"},{"issue":"11","key":"10.1016\/j.parkreldis.2018.12.002_bib33","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.parkreldis.2014.08.013","article-title":"Drooling in Parkinson's disease: a review","volume":"20","author":"Srivanitchapoom","year":"2014","journal-title":"Park. Relat. Disord."},{"issue":"1","key":"10.1016\/j.parkreldis.2018.12.002_bib34","first-page":"75","article-title":"Camptocormia in Parkinson's disease: definition, epidemiology, pathogenesis and treatment modalities","volume":"87","author":"Srivanitchapoom","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.parkreldis.2018.12.002_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2018.11.003","article-title":"Botulinum toxin for Pisa syndrome: an MRI-, ultrasound- and electromyography-guided pilot study","author":"Artusi","year":"2018","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib36","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.parkreldis.2014.07.015","article-title":"Botulinum toxin type A potentiates the effect of neuromotor rehabilitation of Pisa syndrome in Parkinson disease: a placebo controlled study","volume":"20","author":"Tassorelli","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.parkreldis.2018.12.002_bib37","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11910-014-0511-3","article-title":"An update on the use of botulinum toxin therapy in Parkinson's disease","volume":"15","author":"Mills","year":"2015","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"13","key":"10.1016\/j.parkreldis.2018.12.002_bib38","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/mds.22676","article-title":"Goal attainment after treatment of parkinsonian camptocormia with botulinum toxin","volume":"24","author":"Fietzik","year":"2009","journal-title":"Mov. Disord."},{"issue":"6","key":"10.1016\/j.parkreldis.2018.12.002_bib39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/mds.21967","article-title":"Ultrasound-guided injection of the iliopsoas muscle with botulinum toxin in camptocormia","volume":"23","author":"Von Coelln","year":"2008","journal-title":"Mov. Disord."}],"container-title":["Parkinsonism & Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305285?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802018305285?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,17]],"date-time":"2020-11-17T04:27:51Z","timestamp":1605587271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802018305285"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":39,"alternative-id":["S1353802018305285"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.12.002","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.734678524.793554594","asserted-by":"object"}]},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of botulinum toxin in Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2018.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}